Experienced in IgG4-Related Disease

Depei P. Wu

188 Shizi Street, 
Suzhou, CN 
Experienced in IgG4-Related Disease
188 Shizi Street, 
Suzhou, CN 
OverviewLocationsClinical Research

Overview

Depei Wu practices in Suzhou, China. Wu is rated as an Experienced expert by MediFind in the treatment of IgG4-Related Disease. Their top areas of expertise are Leukemia, Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Pancreaticoduodenectomy.

Their clinical research consists of co-authoring 755 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of IgG4-Related Disease.

Locations

188 Shizi Street, Suzhou, 215006, China
Other Locations
22 Hankou Road, Nanjing, 210093, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
A National, Prospective, Non-interventional Study of NINLARO in Real World Clinical Practice
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients with Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia
CD19-targeting Chimeric Antigen Receptor T-cell Therapy for Patients with Refractory and Relapsed B-cell Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Biological
Study Drug: CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: May 06, 2020
Intervention Type: Other, Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

755 Total Publications

Efficacy of venetoclax combined with hypomethylating agents in the treatment of patients newly diagnosed with core binding factor acute myeloid leukemia
Efficacy of venetoclax combined with hypomethylating agents in the treatment of patients newly diagnosed with core binding factor acute myeloid leukemia
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: October 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wu's expertise for a condition
ConditionClose
View All 15 Distinguished Conditions
View All 19 Advanced Conditions
View All 76 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile